PMID- 12811632
OWN - NLM
STAT- MEDLINE
DCOM- 20031014
LR  - 20221207
IS  - 0300-9564 (Print)
IS  - 0300-9564 (Linking)
VI  - 110
IP  - 7
DP  - 2003 Jul
TI  - Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally 
      lesioned rats dopamine independent?
PG  - 707-18
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) has recently been hypothesized to be 
      effective against the symptoms of Parkinson's disease. Therefore we tested the 
      effects of MDMA-derivatives in the rotational behavioural model. Male Sprague 
      Dawley rats were lesioned unilaterally with 6-hydroxydopamine at the medial 
      forebrain bundle. MDMA was administered at doses of 2.5, 5.0 and 10.0 mg/kg, its 
      derivatives N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butananamine (MBDB), 
      3,4-Methylenedioxy-N-ethylamphetamine (MDE) and 3,4-Methylenedioxyamphetamine 
      (MDA) at 5.0 mg/kg respectively. All substances induced ipsilateral rotations, 
      MDA being the most effective. MDMA induced rotations were attenuated by the 
      selective serotonin reuptake inhibitor Citalopram but were only slightly reduced 
      by pre-treatment with the selective serotonin synthesis inhibitor PCPA 
      (para-chlorophenylalanine). The effects of MDMA can therefore not fully be 
      explained by serotonin release or by dopaminergic activity of the drugs.
FAU - Lebsanft, H B
AU  - Lebsanft HB
AD  - Neuropharmacology Institute, University of Tubingen, Germany.
FAU - Mayerhofer, A
AU  - Mayerhofer A
FAU - Kovar, K-A
AU  - Kovar KA
FAU - Schmidt, W J
AU  - Schmidt WJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Austria
TA  - J Neural Transm (Vienna)
JT  - Journal of neural transmission (Vienna, Austria : 1996)
JID - 9702341
RN  - 0 (Adrenergic Agents)
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 103818-46-8 (N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 8HW4YBZ748 (Oxidopamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - ML1I4KK67B (3,4-methylenedioxyethamphetamine)
RN  - N21FAR7B4S (Apomorphine)
RN  - R5J7E3L9SP (Fenclonine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/pharmacology
MH  - Adrenergic Agents/pharmacology
MH  - Animals
MH  - Apomorphine/pharmacology
MH  - Behavior, Animal/drug effects
MH  - Citalopram/pharmacology
MH  - Dopamine/*metabolism
MH  - Fenclonine/pharmacology
MH  - Functional Laterality
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - Medial Forebrain Bundle/*drug effects/*physiopathology
MH  - Models, Animal
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Oxidopamine/pharmacology
MH  - Parkinson Disease/physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rotation
MH  - Serotonin Antagonists/pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/pharmacology
EDAT- 2003/06/18 05:00
MHDA- 2003/10/15 05:00
CRDT- 2003/06/18 05:00
PHST- 2003/06/18 05:00 [pubmed]
PHST- 2003/10/15 05:00 [medline]
PHST- 2003/06/18 05:00 [entrez]
AID - 10.1007/s00702-003-0823-y [doi]
PST - ppublish
SO  - J Neural Transm (Vienna). 2003 Jul;110(7):707-18. doi: 10.1007/s00702-003-0823-y.